Hepatocellular carcinoma

Lancet

Volumn 353, Issue 9160, 1999, Pages 1253-1257

  Schafer, Daniel F ^a   Sorrell, Michael F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS VACCINE; RETINOID;

CANCER SURVIVAL; CHILD; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; PALLIATIVE THERAPY; PRIORITY JOURNAL; SHORT SURVEY; SOCIAL BEHAVIOR; VACCINATION;

EID: 0033541491     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)09148-X     Document Type: Review

References (57)

1. Bosch FX. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver cancer. New York: Churchill Livingstone, 1997: 13-28.
2. Hanley AJG, Choi BCK, Holoway EJ. Cancer mortality among Chinese migrants: a review. Int J Epidemiol 1995; 24: 255-65.
3. Fargion S, Mandelli C, Piperno A, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992; 15: 655-59.
4. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110:1107-19.
5. Beasley RP, Hwang LY, Lin CC, Chein CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981; ii: 1129-33.
6. Beebe GW, Norman JE. Study of the likelihood of hep ato cellular carcinoma following the 1 942 US Army epidemic of hepatitis B. In: Tabor E, Di Bisceglie AM, Purcell RH, eds. Etiology, pathology, and treatment of hepatocellular carcinoma in North America. Houston: Gulf Publishing, 1991: 3-13.
7. Summers J. Three recently described animal virus models for human hepatitis B virus. Hepatology 1981; 1: 179-83.
8. Marion P, Van Davelaar M, Knight S, et al. Hepatocellular carcinoma in ground squirrels persistently infected with ground squirrel hepatitis virus. Proc Natl Acad Sci USA 1986; 83: 4543-546.
9. Lambert V, Cova L, Chevalier M, et al. Natural and experimental infection of wild ducks with DHBV. J Gen Virol 1991; 42: 417-20.
10. Goulliat C, Manganas D, Zoulim F, et al. Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma. J Hepatol 1997; 26: 1324-330.
11. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-72.
12. Okuda K Hepatitis B virus and hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver cancer. New York: Churchill Livingstone, 1997: 39-50.
13. Imai I, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998; 129: 94-99.
14. Austin H. The role of tobacco use and alcohol consumption in the etiology of hepatocellular carcinoma. In: Tabor E, Di Bisceglie AM, Purcell RH, eds. Etiology, pathology, and treatment of hepatocellular carcinoma in North America. Houston: Gulf Publishing, 1991.
15. Nalpas B, Feitelson M, Brechot C, Rubin E. Alcohol, hepatotrophic viruses and hepatocellular carcinoma. Alcohol Clin Exp Res 1995; 19: 1089-95.
16. Takada A, Takase S, Tsutsumi M. Characteristic features of alcoholic liver disease in Japan: a review. Gastroenterol Jap 1993; 28: 181-92.
17. Lasky T, Magder L. Hepatocellular carcinoma p53 G→T transversions at codon 249: the fingerprint of aflatoxin exposure? Environ Health Perspect 1997; 105:392-97.
18. Liver Cancer Study Group of Japan. The general rule for the clinical and pathological study of primary liver cancer, 3rd ed. Tokyo: Kanahara, 1992.
19. Anthony PP, Vogel CL, Barker LF. Liver cell dysplasia: a premalignant condition. J Clin Pathol 1973; 26: 217-23.
20. Watanabe S, Okita K, Harada T, et al. Morphologic studies of the liver cell dysplasia. Cancer 1983; 51: 2197-205.
21. Kondo Y. Pathology of early hepatocellular carcinoma and preneoplastic lesions in the liver. In: Okuda K, Tabor E, eds. Liver cancer. New York: Churchill Livingstone, 1997: 135-53.
22. Ferrell L, Crawford JM, Dhillon AP, et al. Proposal for standardized criteria for the diagnosis of benign, borderline and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993; 17: 23.
23. Lasky T, Magder L. Hepatocellular carcinoma p53 G→T transversions at codon 249: the fingerprint of aflatoxin exposure? Environ Health Perspect 1997; 105: 392-97.
24. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993; 8: 1109-17.
25. Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994; 91: 2230-34.
26. Traunt R, Antunovic J, Greenblatt J, et al. Direct interaction of the hepatitis B virus Hbx protein with p53 leads to inhibition by Hbx of p53 response element-directed transactivation. J Virol 1995; 69: 1851-59.
27. Oda T, Tsuda H, Sakamoto M, Hirohashi S. Different mutations of the p53 gene in nodule-to-nodule hepatocellular carcinoma as evidence for a multistage process. Cancer Lett 1 994; 83: 197-200.
28. Colombo M. Hepatocellular carcinoma in cirrhotics. Semin Liv Dis 1993; 13: 374-83.
29. Ishak KG, Anthony PP, Sobin LH. Histological typing of tumors of the liver. In: WHO International Classification of Tumours, 2nd ed. Berlin: Spinger-Verlag, 1994.
30. Okuda K, Ohtuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985:, 56: 918-28.
31. Hermanek P, Sobin LH, eds. UICC TNM classification of malignant tumors, 4th ed, 2nd rev. Berlin: Springer, 1992.
32. Spiessel B, Beahrs OH, Hermanek P, et al. TMN atlas, 4th ed. Berlin: Springer, 1989.
33. Kew MC. Clinical and nonimaging diagnosis of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver cancer. New York: Churchill Livingstone, 1997: 315-29.
34. Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic function reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997; 26: 1176-81.
35. Lo CM, Lai ECS, Liu CL, et al. Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma. Ann Surgery 1998; 227: 527-32.
36. El-Assal ON, Yamanoi A, Soda Y, et al. Proposal of invasiveness score to predict recurrence and survival after curative resection for hepatocellular carcinoma. Surgery 1997; 122: 571-77.
37. Romani F, Sansalone CV, Rimold P. Liver transplantation for small HCC in chirrhosis. Transplantation 1992; 55: 215-16.
38. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110: 726-34.
39. Leonhardt U, Ritzel U, Ottleben M, et al. Detection of circulating albumin-mRNA by RT-PCR does not indicate metastasizing hepatocellular carcinoma. Langenbecks Arch Chir 1997; 382: 83-86.
40. Van Thiel DH, Carr BI, Yokoyama I, et al. Liver transplantation as a treatment of hepatocellular carcinoma. In: Tabor E, Di Bisceglie AM, Purcell RH, eds. Etiology, pathology, and treatment of hepatocellular carcinoma in North America. Houston: Gulf Publishing, 1991: 309-15.
41. Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: results in 146 patients. Am J Roentgenol 1993; 160: 1023-28.
42. Okuda K, Takayasu K, Okada S. Treatment selection. In: Okuda K, Tabor E, eds. Liver cancer. New York: Churchill Livingstone, 1997: 435-39.
43. Kotoh K, Sakai H, Sakamoto S, et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am J Gastroenterol 1994; 89: 194-98.
44. Bhattacharya S, Davidson B, Dhillon AP. Blood supply of early hepatocellular carcinoma. Semin Liver Dis 1995; 15: 390-401.
45. Stuart K, Stokes K, Jenkins R, et al. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 1993; 72: 3202-09.
46. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oracol 1997; 8: 117-36.
47. Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surgery 1997; 226: 688-703.
48. Okada S, Okazaki N, Nose H, et al. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 1992; 16: 112-17.
49. Castells A, Briux J, Bru G, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-22.
50. Kouromalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42: 442-47.
51. Cottone M, Turri M, Caltagirone M, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8 year prospective study by ultrasound and alfafetoprotein. J Hepatol 1994; 21:1029-34.
52. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered alpha-fetoprotein. N Engl J Med 1993; 328: 1802-06.
53. Colombo M. Screening of patients with chronic liver disease. In: Okuda K, Tabor E, eds. Liver cancer. New York: Churchill Livingstone, 1997: 407-14.
54. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855-59.
55. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of the effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-55.
56. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-02.
57. Muto Y, Moriwaki H, Niomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl JMed 1996; 334: 1561-67.